Efficacy News and Research

RSS

Coley Pharmaceutical licenses VaxImmune to Merck

Coley Pharmaceutical Group has announced that Merck & Co has licensed Coley's VaxImmune vaccine adjuvant for incorporation into vaccines being developed by Merck for certain infectious diseases and Alzheimer's disease.

15 Apr 2007

FDA approves GlaxoSmithKline's antibacterial Altabax

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved its antibacterial Altabax for the topical treatment of impetigo due to susceptible strains of Staphylococcus aureus or Streptococcus pyogenes, the two most common types of bacteria in this kind of infection.

14 Apr 2007

New vaccine to prevent type-1 polio three times as effective as standard vaccine

The study found that each dose of the new monovalent oral poliovirus vaccine, known as mOPV1, protected 30% of susceptible children in northern India against paralytic poliomyelitis. The standard trivalent vaccine in the same setting protected just 11% of children per dose.

12 Apr 2007

Oncolytics Biotech to proceed with phase II Sarcoma trial

Oncolytics Biotech has announced that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN in patients with various sarcomas that have metastasized to the lung.

11 Apr 2007

OHSU surgeon implants donated tissue allografts

Over the years, orthopedic surgeon Dennis Crawford, M.D., Ph.D., of Oregon Health & Science University found it difficult to obtain tissue for transplant to treat some of his patients suffering with severe joint disorders.

11 Apr 2007

Novalar Pharmaceuticals submits NDA for dental anesthetic reversal agent

Novalar Pharmaceuticals, Inc. today announced the submission of a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) for marketing approval of NV-101, a local dental anesthetic reversal agent.

11 Apr 2007

Experimental flu vaccine produced using insect cells shows promise

An influenza vaccine produced with the use of insect cells appeared safe and produced an immunogenic response in healthy adults, suggesting promise as an alternative to using embryonated eggs for the development of influenza vaccine, according to a preliminary study in the April 11 issue of JAMA.

11 Apr 2007

Abbott agrees with WHO to expand access to lopinavir / ritonavir

Abbott and World Health Organization (WHO) Director-General, Margaret Chan, have agreed on a balanced approach to provide Kaletra/Aluvia (lopinavir/ritonavir) capsules and tablets to more patients in the developing world, while supporting continued long-term biopharmaceutical research and development.

10 Apr 2007

Parents well poised to help children overcome bulimia nervosa

Common practice in the treatment of adolescent eating disorder patients has been to exclude the parents. Many experts consider parents part of the problem and thus keep them away during therapy.

10 Apr 2007

Thoracoscopic lobectomy can improve chemotherapy for lung cancer outcomes

Patients who undergo a minimally invasive lung cancer surgery called thoracoscopic lobectomy may derive more benefit from the chemotherapy that follows, according to Duke University Medical Center researchers.

10 Apr 2007

FASgen awarded grant for refinement of its serum fatty acid synthase

FASgen has announced that it has been awarded an SBIR grant from National Cancer Institute for refinement of its serum FAS (fatty acid synthase) ELISA cancer diagnostic test, FAS- Detect ELISA.

10 Apr 2007

China Medicine's ADTZ product highlighted at American Chemical Society's National Meeting

China Medicine Corporation has announced that the Company's proprietary ADTZ product was discussed as a viable means to reduce aflatoxins in the creation of ethanol based products from corn feed at the recent American Chemical Society, 233rd National Meeting Agricultural Biomass, Biobased Products, & Biofuels Symposium, which was held in Chicago, Illinois on March 25th through the 29th.

10 Apr 2007

Largest-ever Parkinson's disease trials

Researchers with the National Institute of Neurological Disorders and Stroke (NINDS) have initiated one of the largest-ever Parkinson's disease clinical trials.

7 Apr 2007

Efficacy of Guanilib confirmed for inflammatory bowel disease

Callisto Pharmaceuticals has announced additional data confirming efficacy of Guanilib, a first-in-class compound currently being developed for the treatment of inflammatory bowel disease (IBD), in two different standard animal models of experimental colitis.

7 Apr 2007

NewYork-Presbyterian and AstraZeneca collaborate in series of cancer studies

NewYork-Presbyterian Hospital is one of six centers nationally to be selected for collaboration with AstraZeneca for an ongoing series of Phase II clinical trials of various novel compounds for potential treatment of a wide variety of cancers.

5 Apr 2007

Combination of sumatriptan and naproxen sodium for migraine more effective than single medications

Combining two different types of treatment for migraine results in better symptom relief than taking either one of the medications, according to a study in the April 4 issue of JAMA .

4 Apr 2007

Women need to be well-informed about mammography screening

Should all women in their 40s be routinely screened for breast cancer? Not necessarily, according to the American College of Physicians.

4 Apr 2007

Inhaled corticosteroids deserve further consideration for lung cancer chemoprevention

Among a group of mostly older male veterans suffering from chronic obstructive pulmonary disease (COPD), an illness that offers a greater susceptibility to lung cancer, researchers found that regular use of high dose inhaled corticosteroids (ICS) lowered the risk of developing lung cancer.

4 Apr 2007

Genelabs Tech reaches agreement with FDA on special protocol assessment for phase III trial of Prestara in lupus

Genelabs Technologies has announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase III clinical trial of Prestara (prasterone) for treatment of systemic lupus erythematosus (lupus).

4 Apr 2007

Boston Scientific announces enrollment in MAPS clinical trial

The MAPS trial (Matrix And Platinum Science) is designed to identify and investigate clinically relevant endpoints for evaluating the efficacy and durability of endovascular treatment of brain aneurysms.

4 Apr 2007